444 related articles for article (PubMed ID: 9456250)
1. Efficacy evaluation of prime-boost protocol: canarypoxvirus-based feline immunodeficiency virus (FIV) vaccine and inactivated FIV-infected cell vaccine against heterologous FIV challenge in cats.
Tellier MC; Pu R; Pollock D; Vitsky A; Tartaglia J; Paoletti E; Yamamoto JK
AIDS; 1998 Jan; 12(1):11-8. PubMed ID: 9456250
[TBL] [Abstract][Full Text] [Related]
2. FIV vaccine studies. I. Immune response to recombinant FIV env gene products and outcome after challenge infection.
Lutz H; Hofmann-Lehmann R; Bauer-Pham K; Holznagel E; Tozzini F; Bendinelli M; Reubel G; Aubert A; Davis D; Cox D
Vet Immunol Immunopathol; 1995 May; 46(1-2):103-13. PubMed ID: 7618250
[TBL] [Abstract][Full Text] [Related]
3. Involvement of gag- and env-specific cytotoxic T lymphocytes in protective immunity to feline immunodeficiency virus.
Flynn JN; Beatty JA; Cannon CA; Stephens EB; Hosie MJ; Neil JC; Jarrett O
AIDS Res Hum Retroviruses; 1995 Sep; 11(9):1107-13. PubMed ID: 8554908
[TBL] [Abstract][Full Text] [Related]
4. Dual-subtype FIV vaccine protects cats against in vivo swarms of both homologous and heterologous subtype FIV isolates.
Pu R; Coleman J; Omori M; Arai M; Hohdatsu T; Huang C; Tanabe T; Yamamoto JK
AIDS; 2001 Jul; 15(10):1225-37. PubMed ID: 11426067
[TBL] [Abstract][Full Text] [Related]
5. Targeted lymph node immunization can protect cats from a mucosal challenge with feline immunodeficiency virus.
Finerty S; Stokes CR; Gruffydd-Jones TJ; Hillman TJ; Barr FJ; Harbour DA
Vaccine; 2001 Oct; 20(1-2):49-58. PubMed ID: 11567745
[TBL] [Abstract][Full Text] [Related]
6. Experimental vaccine protection against feline immunodeficiency virus.
Yamamoto JK; Okuda T; Ackley CD; Louie H; Pembroke E; Zochlinski H; Munn RJ; Gardner MB
AIDS Res Hum Retroviruses; 1991 Nov; 7(11):911-22. PubMed ID: 1662057
[TBL] [Abstract][Full Text] [Related]
7. Effect of dual-subtype vaccine against feline immunodeficiency virus infection.
Hohdatsu T; Okada S; Motokawa K; Aizawa C; Yamamoto JK; Koyama H
Vet Microbiol; 1997 Nov; 58(2-4):155-65. PubMed ID: 9453127
[TBL] [Abstract][Full Text] [Related]
8. Pre-existing immunity to pathogenic Listeria monocytogenes does not prevent induction of immune responses to feline immunodeficiency virus by a novel recombinant Listeria monocytogenes vaccine.
Stevens R; Lavoy A; Nordone S; Burkhard M; Dean GA
Vaccine; 2005 Feb; 23(12):1479-90. PubMed ID: 15670884
[TBL] [Abstract][Full Text] [Related]
9. Dual-subtype vaccine (Fel-O-Vax FIV) protects cats against contact challenge with heterologous subtype B FIV infected cats.
Kusuhara H; Hohdatsu T; Okumura M; Sato K; Suzuki Y; Motokawa K; Gemma T; Watanabe R; Huang C; Arai S; Koyama H
Vet Microbiol; 2005 Jul; 108(3-4):155-65. PubMed ID: 15899558
[TBL] [Abstract][Full Text] [Related]
10. Mechanism(s) of FIV vaccine protection.
Pu R; Tellier MC; Yamamoto JK
Leukemia; 1997 Apr; 11 Suppl 3():98-101. PubMed ID: 9209311
[TBL] [Abstract][Full Text] [Related]
11. Partial protection by vaccination with recombinant feline immunodeficiency virus surface glycoproteins.
Leutenegger CM; Hofmann-Lehmann R; Holznagel E; Cuisinier AM; Wolfensberger C; Duquesne V; Cronier J; Allenspach K; Aubert A; Ossent P; Lutz H
AIDS Res Hum Retroviruses; 1998 Feb; 14(3):275-83. PubMed ID: 9491919
[TBL] [Abstract][Full Text] [Related]
12. Protection against FIV challenge infection by genetic vaccination using minimalistic DNA constructs for FIV env gene and feline IL-12 expression.
Boretti FS; Leutenegger CM; Mislin C; Hofmann-Lehmann R; König S; Schroff M; Junghans C; Fehr D; Huettner SW; Habel A; Flynn JN; Aubert A; Pedersen NC; Wittig B; Lutz H
AIDS; 2000 Aug; 14(12):1749-57. PubMed ID: 10985311
[TBL] [Abstract][Full Text] [Related]
13. Immunization of cats against feline immunodeficiency virus (FIV) infection by using minimalistic immunogenic defined gene expression vector vaccines expressing FIV gp140 alone or with feline interleukin-12 (IL-12), IL-16, or a CpG motif.
Leutenegger CM; Boretti FS; Mislin CN; Flynn JN; Schroff M; Habel A; Junghans C; Koenig-Merediz SA; Sigrist B; Aubert A; Pedersen NC; Wittig B; Lutz H
J Virol; 2000 Nov; 74(22):10447-57. PubMed ID: 11044089
[TBL] [Abstract][Full Text] [Related]
14. Prime-boost vaccination using DNA and whole inactivated virus vaccines provides limited protection against virulent feline immunodeficiency virus.
Dunham SP; Bruce J; Klein D; Flynn JN; Golder MC; MacDonald S; Jarrett O; Neil JC
Vaccine; 2006 Nov; 24(49-50):7095-108. PubMed ID: 17049683
[TBL] [Abstract][Full Text] [Related]
15. Protection against homologous but not heterologous challenge induced by inactivated feline immunodeficiency virus vaccines.
Hosie MJ; Osborne R; Yamamoto JK; Neil JC; Jarrett O
J Virol; 1995 Feb; 69(2):1253-5. PubMed ID: 7815500
[TBL] [Abstract][Full Text] [Related]
16. Dual-subtype FIV vaccine (Fel-O-Vax FIV) protection against a heterologous subtype B FIV isolate.
Pu R; Coleman J; Coisman J; Sato E; Tanabe T; Arai M; Yamamoto JK
J Feline Med Surg; 2005 Feb; 7(1):65-70. PubMed ID: 15686976
[TBL] [Abstract][Full Text] [Related]
17. Env-specific CTL predominate in cats protected from feline immunodeficiency virus infection by vaccination.
Flynn JN; Keating P; Hosie MJ; Mackett M; Stephens EB; Beatty JA; Neil JC; Jarrett O
J Immunol; 1996 Oct; 157(8):3658-65. PubMed ID: 8871667
[TBL] [Abstract][Full Text] [Related]
18. Immunization-induced decrease of the CD4+:CD8+ ratio in cats experimentally infected with feline immunodeficiency virus.
Lehmann R; von Beust B; Niederer E; Condrau MA; Fierz W; Aubert A; Ackley CD; Cooper MD; Tompkins MB; Lutz H
Vet Immunol Immunopathol; 1992 Dec; 35(1-2):199-214. PubMed ID: 1363009
[TBL] [Abstract][Full Text] [Related]
19. HIV-1 p24 vaccine protects cats against feline immunodeficiency virus infection.
Coleman JK; Pu R; Martin M; Sato E; Yamamoto JK
AIDS; 2005 Sep; 19(14):1457-66. PubMed ID: 16135898
[TBL] [Abstract][Full Text] [Related]
20. Passive antibody protection of cats against feline immunodeficiency virus infection.
Hohdatsu T; Pu R; Torres BA; Trujillo S; Gardner MB; Yamamoto JK
J Virol; 1993 Apr; 67(4):2344-8. PubMed ID: 8383246
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]